Posted by Michael Wonder on 27 Mar 2024
Syndax announces FDA priority review of NDA for revumenib for the treatment of relapsed/refractory KMT2Ar acute leukaemia
26 March 2024 - PDUFA action date set for 26 September 2024.
Syndax Pharmaceuticals today announced that the US FDA has granted Priority Review for its new drug application for revumenib, the Company's first in class menin inhibitor, for the treatment of adult and paediatric relapsed or refractory KMT2A-rearranged acute leukemia.
